土耳其肥胖症现状：生态系统、市场动态及司美格鲁肽专利到期的影响

The Obesity Landscape in Türkiye Ecosystem, market dynamics and the impact of semaglutide LoE SİNEM ERTEN, Associate DirectorZÜLEYHA CEBECİ HİÇYILMAZ, Senior ConsultantASLIHAN İKİZOĞLU, Senior Consultant Table of contents Executive summary11. Obesity: A serious public health burden32. Obesity management ecosystem62.1. Preventive policies62.2. Diagnostic framework72.3. Treatment modalities72.3.1. Non-pharmacological lifestyle modifications72.3.2. Digital solutions in obesity management72.3.3. Pharmacological treatment92.3.4. Bariatric surgery102.4. Patient journey112.4.1. Key specialties in obesity management112.4.2. Role of pharmacists122.4.3. Pharmacological treatment approach132.4.4. Patient initiated demand for obesity medications142.4.5. Key challenges in obesity management and patient journey142.4.6. Drivers of medication switch172.4.7. Long-term continuation and maintenance172.4.8. Upcoming change in the treatment landscape: Oral formulations183. Obesity market dynamics203.1. GLP-1 therapies: Market formation203.1.1. GLP-1 therapies in the Turkish pharmaceutical market203.1.2. Brand awareness for obesity medications in Türkiye223.2. Future outlook for obesity market233.2.1. Global obesity market forecast233.2.2. Türkiye perspective: Growth drivers and barriers for GLP-1 market234. What to expect after Semaglutide’s LoE?26Explanations28References29About the authors30Acknowledgements31Abbreviations32 FIGURES Figure 1: Online services for obesity management in Europe08Figure 2: Roles by multiple stakeholders in obesity care pathway12Figure 3: Patients’ reported negative experiences with obesity medications15Figure 4: Patients’ reported top reasons for switch of obesity medication17Figure 5: Expectations of patients during the maintenance phase18Figure 6: Monthly sales during post-launch for selected GLP-1 agents in Türkiye21Figure 7: Private market sales for Wegovy and Mounjaro by country21Figure 8: Top of mind awareness (first mention) by drug classes/molecules22 TABLES Table 1: GLP-1 treatments with market authorization in Türkiye20Table 2: Growth drivers for GLP-1 market in Türkiye24Table 3: Current barriers for GLP-1 market in Türkiye25 Executive summary Obesity has emerged as one of the most critical and fast growing publichealth challenges globally and in Türkiye, with significant clinical, economic,and societal burden. Türkiye is among the countries with highest obesityprevalence in the world. More than one-third of adults are living with obesitytoday, and projections indicate that more than half of the adult populationcould be living with obesity by 2035. This trajectory is expected to significantlyincrease the burden of diabetes, cardiovascular disease and other non-communicable diseases while also creating substantial economic pressure onthe healthcare system. This underscores the urgency of coordinated long-termpolicy and system responses. This white paper presents a comprehensiveassessment of the obesity ecosystem in Türkiye,combining epidemiology, public policy frameworks,healthcare delivery pathways, patient and healthcareprofessional insights, and market dynamics. Ithighlights obesity not only as a medical condition butalso as a chronic disease with a substantial emotionaland economic burden, characterized by delayed careseeking behaviors, fragmented treatment pathways,and high rates of treatment discontinuation. variability in the use of broader metabolic riskassessment tools across specialties. The treatment landscape in Türkiye is evolving rapidly,parallel to changes in global environment. Lifestyleinterventions remain the cornerstone of obesitymanagement, while pharmacological therapiesparticularly GLP-1 treatments are increasinglyreshaping clinical practice. Physician insights revealgrowing confidence in obesity medicines, supportedby accumulated experience and emerging globalguidelines. At the same time, affordability issuesand limited post-prescription support remain keychallenges affecting treatment initiation, adherence,and long-term continuation. Endocrinologists,internists and cardiologists are taking active role inthe management of obesity while family physiciansmainly focus on screening and referral. Obesity has anon-linear, multi-entry care pathway, with pharmacistsemerging as increasingly important stakeholderswithin the obesity ecosystem due to frequentpatient interaction and high accessibility. However,pharmacists currently operate within a structurallyunderdefined role despite their growing influence ontreatment continuation and patient behavior. Obesity is recognized as a chronic disease leadingto a wide range of diseases and is considered asignificant public health challenge by Ministry ofHealth. Türkiye has established a national action planincluding a prevention infrastructure through primarycare screening and awareness programs, supportedwith a network of Healthy Life Centers. The Ministryof Health’s obesity initiatives including nationwideoutreach to a